Total Payments
$586,688
2024 Payments
$11,401
Companies
31
Transactions
342
Medicare Patients
1,028
Medicare Billing
$198,156
Payment Breakdown by Category
Consulting$524,012 (89.3%)
Other$38,045 (6.5%)
Travel$10,411 (1.8%)
Food & Beverage$9,420 (1.6%)
Research$4,800 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $524,012 | 148 | 89.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,705 | 6 | 3.5% |
| Honoraria | $17,340 | 5 | 3.0% |
| Travel and Lodging | $10,411 | 50 | 1.8% |
| Food and Beverage | $9,420 | 129 | 1.6% |
| Unspecified | $4,800 | 4 | 0.8% |
Payments by Type
General
$581,888
338 transactions
Research
$4,800
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $159,478 | 93 | $0 (2024) |
| PFIZER INC. | $79,923 | 32 | $0 (2024) |
| UROGEN PHARMA, INC. | $76,141 | 28 | $0 (2024) |
| Photocure Inc | $72,054 | 52 | $0 (2023) |
| Janssen Research & Development, LLC | $40,654 | 12 | $0 (2023) |
| Ferring Pharmaceuticals Inc. | $40,496 | 26 | $0 (2023) |
| Janssen Global Services, LLC | $18,128 | 21 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $16,690 | 15 | $0 (2021) |
| Nonagen Bioscience Corp | $11,594 | 2 | $0 (2023) |
| Seagen Inc. | $10,893 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,401 | 12 | Endo USA, Inc. ($4,250) |
| 2023 | $67,786 | 29 | UroGen Pharma, Inc. ($29,489) |
| 2022 | $73,377 | 31 | UroGen Pharma, Inc. ($46,018) |
| 2021 | $52,068 | 36 | PFIZER INC. ($8,730) |
| 2020 | $113,373 | 44 | Merck Sharp & Dohme Corporation ($47,893) |
| 2019 | $176,876 | 91 | Merck Sharp & Dohme Corporation ($55,151) |
| 2018 | $52,603 | 60 | Merck Sharp & Dohme Corporation ($23,680) |
| 2017 | $39,204 | 39 | Merck Sharp & Dohme Corporation ($20,569) |
All Payment Transactions
342 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 12/18/2024 | Endo USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 12/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $545.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $33.15 | General |
| Category: Oncology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $57.29 | General |
| Category: Oncology | ||||||
| 06/27/2024 | IMMUNITYBIO, INC. | ANKTIVA (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Immunotherapy | ||||||
| 06/19/2024 | PFIZER INC. | PADCEV (Biological) | Honoraria | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 05/31/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $71.24 | General |
| Category: Oncology | ||||||
| 05/31/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $39.11 | General |
| Category: Oncology | ||||||
| 05/29/2024 | Endo USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,450.00 | General |
| 05/03/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $30.98 | General |
| Category: UROTHELIAL CANCER | ||||||
| 05/03/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: Oncology | ||||||
| 12/13/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,907.50 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2023 | Photocure Inc | CYSVIEW (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2023 | Photocure Inc | CYSVIEW (Drug) | Food and Beverage | In-kind items and services | $268.16 | General |
| Category: ONCOLOGY | ||||||
| 12/01/2023 | UroGen Pharma, Inc. | — | Honoraria | Cash or cash equivalent | $4,000.00 | General |
| 12/01/2023 | UroGen Pharma, Inc. | — | Travel and Lodging | In-kind items and services | $454.46 | General |
| 12/01/2023 | UroGen Pharma, Inc. | — | Food and Beverage | In-kind items and services | $234.93 | General |
| 11/30/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,074.00 | General |
| 11/29/2023 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Drug) | Food and Beverage | In-kind items and services | $156.15 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2023 | Boston Scientific Corporation | LithoVue (Device) | Food and Beverage | In-kind items and services | $41.59 | General |
| Category: LithoVue_URO | ||||||
| 11/09/2023 | Medtronic, Inc. | INTERSTIM (Device) | Food and Beverage | In-kind items and services | $157.96 | General |
| Category: Sacral Nerve Stimulation | ||||||
| 11/06/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 11/02/2023 | Nonagen Bioscience Corp | Oncuria (Device) | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 11/01/2023 | UroGen Pharma, Inc. | — | Consulting Fee | Cash or cash equivalent | $15,200.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| SASANLIMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| RN888 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 66 | 83 | $82,654 | $7,010 |
| 2022 | 10 | 356 | 6,210 | $650,625 | $73,812 |
| 2021 | 10 | 311 | 2,710 | $494,406 | $58,375 |
| 2020 | 11 | 295 | 4,746 | $474,230 | $58,959 |
Total Patients
1,028
Total Services
13,749
Medicare Billing
$198,156
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 32 | 32 | $75,904 | $5,051 | 6.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $5,580 | $1,825 | 32.7% |
| 81002 | Urinalysis, manual test | Office | 2023 | 22 | 39 | $1,170 | $132.99 | 11.4% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2022 | 77 | 133 | $315,476 | $30,007 | 9.5% |
| 51720 | Instillation of anti-cancer drug into bladder | Office | 2022 | 31 | 153 | $147,645 | $12,426 | 8.4% |
| J9030 | Bcg live intravesical instillation, 1 mg | Office | 2022 | 28 | 5,515 | $55,150 | $11,999 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 45 | 63 | $34,650 | $6,864 | 19.8% |
| 52235 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | Facility | 2022 | 11 | 13 | $30,849 | $3,340 | 10.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 31 | 37 | $13,875 | $2,950 | 21.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $17,946 | $2,803 | 15.6% |
| 52234 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | Facility | 2022 | 11 | 11 | $22,297 | $2,335 | 10.5% |
| 81002 | Urinalysis, manual test | Office | 2022 | 80 | 238 | $7,140 | $817.26 | 11.4% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2022 | 24 | 29 | $5,597 | $270.68 | 4.8% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2021 | 61 | 109 | $234,912 | $23,128 | 9.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 48 | 67 | $36,850 | $7,674 | 20.8% |
| 51720 | Instillation of anti-cancer drug into bladder | Office | 2021 | 20 | 74 | $71,410 | $6,188 | 8.7% |
| J9030 | Bcg live intravesical instillation, 1 mg | Office | 2021 | 16 | 2,181 | $21,810 | $4,747 | 21.8% |
| 52235 | Destruction and/or removal of (2.0 to 5.0 centimeters) medium growths of the bladder and bladder canal (urethra) using an endoscope | Facility | 2021 | 19 | 19 | $45,087 | $4,743 | 10.5% |
| 52234 | Destruction and/or removal of (0.5 to 2.0 centimeters) small growths of the bladder using an endoscope | Facility | 2021 | 19 | 19 | $38,513 | $4,204 | 10.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 22 | 23 | $17,135 | $3,937 | 23.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 19 | 19 | $18,649 | $2,893 | 15.5% |
| 81002 | Urinalysis, manual test | Office | 2021 | 68 | 173 | $5,190 | $602.04 | 11.6% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2021 | 19 | 26 | $4,850 | $259.75 | 5.4% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2020 | 47 | 71 | $124,250 | $13,970 | 11.2% |
| 51720 | Bladder instillation of cancer preventive, inhibiting, or suppressive agent | Office | 2020 | 21 | 118 | $113,869 | $9,273 | 8.1% |
About Gary Steinberg, M D
Gary Steinberg, M D is a Urology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2007. The National Provider Identifier (NPI) number assigned to this provider is 1558585307.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Gary Steinberg, M D has received a total of $586,688 in payments from pharmaceutical and medical device companies, with $11,401 received in 2024. These payments were reported across 342 transactions from 31 companies. The most common payment nature is "Consulting Fee" ($524,012).
As a Medicare-enrolled provider, Steinberg has provided services to 1,028 Medicare beneficiaries, totaling 13,749 services with total Medicare billing of $198,156. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Chicago, IL
- Active Since 04/12/2007
- Last Updated 04/02/2021
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1558585307
Products in Payments
- KEYTRUDA (Biological) $88,375
- Cysview (Drug) $63,056
- V937 (Biological) $13,750
- PADCEV (Biological) $13,400
- Oncuria (Device) $11,594
- IMFINZI (Drug) $6,715
- CYSVIEW (Drug) $6,498
- Trelstar (Drug) $6,362
- BALVERSA (Drug) $5,813
- TECENTRIQ (Biological) $5,515
- Padcev (Drug) $4,883
- ONCOZENE (Device) $4,000
- RF 3000 (Device) $4,000
- LIBTAYO (Biological) $3,450
- ANKTIVA (Drug) $2,400
- OPDIVO (Biological) $2,142
- JELMYTO (Drug) $1,631
- GENERAL THERAPIES (Device) $1,393
- GENERAL - THERAPIES (Device) $283.48
- THERAPIES (Device) $274.17
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Chicago
Simone Crivellaro, Md, MD
Urology — Payments: $459,193
Urology $459,193
Dr. Ashley Ross
Urology — Payments: $382,611
Urology $382,611
Brian Helfand, M.d./Ph.d, M.D./PH.D
Urology — Payments: $380,392
Urology $380,392
Amy Krambeck, M.d, M.D
Urology — Payments: $350,930
Urology $350,930
Dr. Kevin Zorn, M.d, M.D
Urology — Payments: $302,808
Urology $302,808
Laurence Levine, Md, MD
Urology — Payments: $287,103
Urology $287,103